Evidence map›Paper›PMID 31699751›Full record

ArticleBMJ open2019

Best emollients for eczema (BEE) - comparing four types of emollients in children with eczema: protocol for randomised trial and nested qualitative study.

Matthew J Ridd, Sian Wells, Louisa Edwards, Miriam Santer, Stephanie MacNeill, Emily Sanderson, Eileen Sutton, Alison R G Shaw, Jonathan Banks, Kirsty Garfield and 8 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. How parents and children evaluate emollients for childhood eczema: a qualitative study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2022
    Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Matthew J RiddCentre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK m.ridd@bristol.ac.uk.ORCID 0000-0002-7954-8823
Sian WellsCentre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK.
Louisa EdwardsFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.ORCID 0000-0001-9371-2805
Miriam SanterPrimary Care and Population Sciences, University of Southampton, Southampton, UK.
Stephanie MacNeillBristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.
Emily SandersonBristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.
Eileen SuttonCentre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK.
Alison R G ShawCentre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK.
Jonathan BanksNational Institute for Health Research Collaborations for Leadership in Applied Health Research and Care West (NIHR CLAHRC West), University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Kirsty GarfieldBristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.
Amanda RobertsNottingham Support Group for Carers of Children with Eczema, Nottingham, UK.
Tiffany J BarrettSouth West Medicines Information & Training, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Helen BaxterCentre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK.
Jodi TaylorBristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.
J Athene LaneBristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.
Alastair D HayCentre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK.
Hywel C WilliamsCentre of Evidence-Based Dermatology, University of Nottingham, Nottingham, UK.
Kim Suzanne ThomasCentre of Evidence-Based Dermatology, University of Nottingham, Nottingham, UK.ORCID 0000-0001-7785-7465
At Bristol · GBUniversity of Bristol · GBUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity of Nottingham · GBSimon Fraser University · CAUniversity of Southampton · GB

Funding

Department of Health 15/130/07Department of Health HTA/15/130/07Department of Health PDF-2014-07-013Medical Research Council MR/K025643/1
6 · The paper itself

Abstract

introductionAtopic dermatitis/eczema affects around 20% of children and is characterised by inflamed, dry, itchy skin. Guidelines recommend 'leave-on' emollients that are applied directly to the skin to add or trap moisture and used regularly, they can soothe, enhance the skin barrier and may prevent disease 'flares'. However, the suitability of the many different emollients varies between people and there is little evidence to help prescribers and parents and carers decide which type to try first. METHODS AND ANALYSIS: Design: pragmatic, multicentre, individually randomised, parallel group superiority trial of four types of emollient (lotions, creams, gel or ointments).

settinggeneral practitioner surgeries in England.

participantschildren aged over 6 months and less than 12 years with mild-to-severe eczema and no known sensitivity to study emollients.

interventionsstudy-approved lotion, cream, gel or ointment as the only leave-on emollient for 16 weeks, with directions to apply twice daily and as required. Other treatments, such as topical corticosteroids, used as standard care. FOLLOW-UP: 52 weeks. PRIMARY OUTCOME: validated patient-orientated eczema measure measured weekly for 16 weeks. SECONDARY OUTCOMES: eczema signs (Eczema Area Severity Index) by masked researcher, treatment use, parent satisfaction, adverse events, child and family quality of life (Atopic Dermatitis Quality of Life, Child Health Utility 9D and Dermatitis Family Impact). SAMPLE SIZE: 520 participants (130 per group). ANALYSIS: intention-to-treat using linear mixed models for repeated measures.Nested qualitative study: audio-recording of sample of baseline appointments and up to 60 interviews with participants at 4 and 16 weeks, interviews to be transcribed and analysed thematically. ETHICS AND DISSEMINATION: Ethics approval granted by the NHS REC (South West - Central Bristol Research Ethics Committee 17/SW/0089). Findings will be presented at conferences, published in open-access peer-reviewed journals and the study website; and summaries shared with key stakeholders. TRIAL REGISTRATION NUMBER: ISRCTN84540529.

Indexed as

ChildCost-Benefit AnalysisEczemaEmollientsEnglandEquivalence Trials as TopicHumansMulticenter Studies as TopicParentsPersonal SatisfactionPragmatic Clinical Trials as TopicQualitative ResearchQuality of LifeSeverity of Illness IndexTreatment OutcomeEmollientseczemapaediatric dermatologytherapeutics

Identifiers

PMID31699751
PMCPMC6858146
OpenAlexW2987095542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.